MedTrace Logo

Stem Cell Therapy for Limbal Stem Cell Deficiency

NCT03957954 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-10

No results posted yet for this study

Summary

This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).

Conditions

  • Limbal Stem-cell Deficiency

Interventions

BIOLOGICAL

cLSC

Transplantation of cLSC

DEVICE

Scleral contact lens (SCL)

Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.

Sponsors & Collaborators

Principal Investigators

  • Sophie Deng, MD, PhD · Stein Eye Institute UCLA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2027-02-04
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03957954 on ClinicalTrials.gov